Gerresheimer AG’s shares advanced 5.9% on Monday, lifting the stock to €26.74 after preliminary first-quarter 2026 results showed modest revenue growth but a decline in profitability.
The Düsseldorf-based pharmaceutical packaging specialist reported adjusted revenue of €524 million, up from €519 million in the year-ago period. Adjusted EBITDA fell to €66 million from €81 million, while the EBITDA margin contracted to 12.6% from 15.7%, reflecting the company’s strategic pivot toward cash generation over near-term profitability.
The preliminary results follow a reduction to Gerresheimer’s 2026 revenue guidance, which was lowered to the lower half of its €2.3–€2.4 billion target range. Management’s updated outlook emphasized improved free cash flow and a more constructive tone on second-half performance, contributing to the stock’s rebound after a period of range-bound trading in the upper €20s.
Leadership changes at the helm also coincided with Monday’s gains. Uwe Röhrhoff, Gerresheimer’s CEO, is set to step down, with interim joint successors Wolf Lehmann and Achim Schalk assuming responsibilities on a temporary basis starting August 24, 2026. The transition was confirmed earlier this month.
The company’s business centers on specialized pharmaceutical and cosmetic packaging, injectable drug delivery systems, and self-administration devices. Shares remain well below their 52-week high of €45.24, though Monday’s gain aligns with broader strength in U.S. equity indices and positive momentum for German mid-cap equities.
Gerresheimer is listed on the SDAX index.
